Eli Lilly CEO said he believed the company could find “significant common cause” with the Trump administration, even if there ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Heading into fiscal 2025, CEO David Ricks said the company expects sales of weight-loss drugs will continue growing, and noted that it expects "to produce at least 60% more salable doses" of the drugs ...
Leerink notes that Eli Lilly (LLY) lowered its Q4 total revenue guidance by 5% but issued initial 2025 revenue guidance 2% above consensus. Q4 ...
Hosted on MSN6h
Eli Lilly Stock Faces Worst Day In Nearly 4 Years On Q4 Weight-Loss Drug Sales Miss, But Retail Bullish On 2025 ProjectionsShares of Eli Lilly & Co. dropped over 7% on Tuesday morning, reaching levels last seen in late November and marking the ...
The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...
Hosted on MSN6h
Eli Lily cuts 2024 revenue guidance by $400M, shares sink 8%Eli Lilly saw its shares crash in early trade on Tuesday as the pharm major provided its revenue outlook for 2024 and 2025.
Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...
Eli Lilly (LLY) stock fell as its obesity therapy tirzepatide missed forecasts, amid focus on compounded weight loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback